Here are the 8-K filings from Biotricity Inc (BTCY) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An 8-K covers material events a company has to report between its quarterly reports, so if you follow BTCY and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BTCY filings page.
BIOTRICITY INC. (BTCY) reported that Jainal Bhuiyan resigned as a director and member of its Compensation Committee, effective September 22, 2026. He had served as a director since August 15, 2024; the company said his resignation did not result from disagreement over its operations, policies or practices.
After the resignation, the board has three directors: Waqaas Al-Siddiq, David A. Rosa and Ronald McClurg. Ronald McClurg was appointed to the Compensation Committee, which consists of him and chairman David A. Rosa. The Audit Committee and Nominating and Corporate Governance Committee compositions are unchanged. The board has not yet determined whether to fill the vacancy or reduce its size.
Biotricity Inc. entered exchange agreements on May 1, 2026 with holders of 14,144,325 common shares, options for 3,992,427 shares, and warrants for 1,436,216 shares. These securities were exchanged for 1,957,297 shares of newly created Series C Preferred Stock on a ten‑for‑one basis.
The company designated 2,100,000 Series C Preferred shares, each carrying 40 votes. After any equity financing raising at least $15 million, outstanding Series C will automatically convert into 59.6% of Biotricity’s common stock. If no such financing occurs by March 31, 2028, each Series C share may convert into 10 common shares.
Biotricity Inc. reported solid third-quarter fiscal 2026 results, with revenue rising 10.2% to $4 million from $3.6 million a year earlier. The company highlighted its third consecutive quarter of positive EBITDA and net operating income, reflecting growing adoption of its remote cardiac monitoring solutions.
Gross margin improved to 81.5% from 76.4%, helped by a larger recurring technology-fee base and AI-driven efficiencies. Net loss narrowed to $1.1 million, or $0.042 per share, compared with $1.3 million, or $0.054 per share. Management also pointed to strong customer retention above 90% and ongoing international expansion.
Biotricity Inc. reported that it has released its financial results for the period ended September 30, 2025. The company announced these results through a press release dated November 14, 2025, which is included as Exhibit 99.1. The notice clarifies that this earnings information is being furnished under a current report and is not deemed filed for liability purposes under the securities laws unless specifically incorporated by reference elsewhere.